Aclaris Therapeutics Begins Phase 1 Clinical Trial for Bispecific Antibody ATI-052 Targeting Inflammatory Diseases

Aclaris Therapeutics Inc. (NASDAQ:ACRS) is one of the best low priced pharma stocks to buy now. On June 23, Aclaris Therapeutics initiated a placebo-controlled Phase 1a/1b program for its investigational bispecific antibody, called ATI-052. This program follows the recent IND clearance from the US FDA for ATI-052.

The Phase 1a portion will involve single ascending dose/SAD and multiple ascending dose/MAD studies in healthy volunteers to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneously administered ATI-052. ATI-052 is designed as a potential best-in-class bispecific anti-thymic stromal lymphopoietin/TSLP and anti-interleukin-4 receptor/IL-4R antibody.

The design allows for high binding affinity and dual blockade of both upstream TSLP receptor signal transduction and downstream IL-4R activation. The dual targeting selectively inhibits central proinflammatory pathways involved in Th2-mediated inflammation and allergic diseases by blocking TSLP, which is at the top of the inflammatory cascade, and both downstream IL-4 and IL-13, which are key cytokines in these conditions.

Aclaris Therapeutics Inc. (NASDAQ:ACRS) is a clinical-stage biopharmaceutical company that develops novel drug candidates for immune-inflammatory diseases in the US.

While we acknowledge the potential of ACRS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.